Psychosocial Factors and Quality of Life in the Effect of Fear of COVID-19 With Cystic Fibrosis

NCT05195216 | Completed

• 1 other identifier: MedipolU-KABASAKAL-001
• Study Type: observational
• Target: 128
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study; The COVID-19 pandemic is to investigate the effects of COVID-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.

Conditions

Cystic Fibrosis

Outcome Measures

Primary Outcomes (1)

• fear of covid-19

  COVID-19 Fear Scale: This scale is a one-dimensional instrument consisting of seven items with robust psychometric properties that measure fear of COVID-19. It has a 5-point Likert-type rating system (1: Strongly disagree, 5: Strongly agree). It is reliable and valid in assessing fear of COVID-19 among the general population. Turkish validity and reliability of the scale were ensured.

  November- December/2021

Secondary Outcomes (1)

• psychosocial factors

  November-December/2021November-December/2021

Other Outcomes (1)

• quality of life assessment

  November-December/2021November-December/2021

Study Arms (2)

individuals with cystic fibrosis

Behavioral: Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

healthy individuals

Behavioral: Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form

Interventions

Survey Form, The Hospital Anxiety and Depression Scale, The Fear of COVID-19 Scale,World Health Organization Quality of Life Scale- Bref Form BEHAVIORAL

Online questionnaires were administered to individuals.

healthy individuals; individuals with cystic fibrosis

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

64 individuals with cystic fibrosis and 70 healthy individuals participated in the study.

You may qualify if:

• be 16 years of age or older
• Having been diagnosed with Cystic Fibrosis
• Volunteering to participate in the research

You may not qualify if:

• Being mentally incapable of successfully applying the scales to be applied for evaluation purposes
• Being treated with sedative and antiepileptic drugs
• Pregnancy

Sponsors & Collaborators

• Elif Kabasakal: lead

Study Sites (1)

Elif Kabasakal

Istanbul, İ̇stanbul, 34734, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Infant, Newborn, Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: ekabasakal

Study Record Dates

• First Submitted: January 13, 2022
• First Posted: January 18, 2022
• Study Start: November 20, 2021
• Primary Completion: November 30, 2021
• Study Completion: December 25, 2021
• Last Updated: January 18, 2022

Record last verified: 2022-01

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)